ACE Inhibitors for Hypertension Management

Introduction to ACE Inhibitors

The American Heart Association recommends ACE inhibitors as first-line therapy for hypertension, with treatment initiated at low doses and gradually titrated to target doses that have demonstrated cardiovascular event reduction in clinical trials 1, 2, 3

Initial therapy should begin with low doses, followed by gradual dose increments if well tolerated, with the American College of Cardiology suggesting doses such as Captopril: 6.25 mg three times daily, titrate to 50 mg three times daily, Enalapril: 2.5 mg twice daily, titrate to 10-20 mg twice daily, and Ramipril: 1.25-2.5 mg once daily, titrate to 10 mg once daily 2
For patients with blood pressure ≥160/100 mmHg, consider initial therapy with two antihypertensive medications, such as an ACE inhibitor plus a thiazide diuretic, as recommended by the American Diabetes Association 4

ACE inhibitors are particularly beneficial for patients with heart failure with reduced ejection fraction (HFrEF) 1, 2, 3, coronary artery disease 5, 4, diabetes mellitus 4, and chronic kidney disease, especially with albuminuria 4, 6
Use ACE inhibitors with caution in patients with very low systolic blood pressure (<80 mm Hg) 2, markedly increased serum creatinine (>3 mg/dL) 2, bilateral renal artery stenosis 2, and elevated serum potassium (>5.0 mEq/L) 2

Assess renal function and serum potassium within 1-2 weeks of initiation and periodically thereafter, with more frequent monitoring recommended for patients with preexisting hypotension, hyponatremia, diabetes mellitus, azotemia, and those taking potassium supplements 2, 4
ACE inhibitors are contraindicated in patients with history of angioedema 2 and pregnancy or women planning to become pregnant 2

ACE inhibitors should not be combined with ARBs or direct renin inhibitors due to increased risk of adverse events (hyperkalemia, syncope, acute kidney injury) 4
Abrupt withdrawal of ACE inhibitors should be avoided as it can lead to clinical deterioration 2
For patients who develop intolerable cough with ACE inhibitors, an ARB may be substituted as an alternative 6
In patients with diabetes and hypertension, ACE inhibitors are recommended as first-line therapy, particularly in those with albuminuria 4
For patients with chronic kidney disease (stage 3 or higher or stage 1-2 with albuminuria), ACE inhibitors are reasonable to slow kidney disease progression 6

The American Diabetes Association recommends ACE inhibitors for patients with urinary albumin excretion >300 mg/day (macroalbuminuria), with Grade A evidence supporting this approach 7, 8
The American Diabetes Association and KDIGO guidelines suggest starting with a low dose ACE inhibitor and uptitrating to the maximally tolerated dose, as ACE inhibitors are indicated for macroalbuminuria (≥300 mg/day) regardless of blood pressure status 7, 9

The KDIGO 2021 guidelines reinforce that ACE inhibitors should be uptitrated to maximally tolerated doses as first-line therapy for proteinuria, even in the absence of hypertension 9, 10, 11
Target the maximum tolerated dose rather than stopping at initial response 9, 10

Check serum creatinine and potassium within 1-2 weeks of initiation and after each dose increase, and accept up to 30% increase in serum creatinine as expected 7, 9, 10
Stop ACE inhibitor only if: creatinine continues to rise beyond 30%, refractory hyperkalemia develops, or acute kidney injury occurs 9, 10
Monitor urine albumin excretion periodically to assess treatment response 7, 8

Restrict sodium to <2.0 g/day (<90 mmol/day) to maximize ACE inhibitor efficacy 9, 11

Counsel the patient to hold ACE inhibitor during volume depletion to prevent acute kidney injury 9, 10, 11
Use potassium-wasting diuretics or potassium binders if hyperkalemia develops, rather than stopping the ACE inhibitor 9, 11